Stock Analiz

Q/c Technologies, Inc. QCLS

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2014 · data as of November 13, 2026

$0.31Market cap $3M
Open the interactive analysis →

Q/c Technologies, Inc. (QCLS) is a healthcare company listed in the US with a market value of about $3M.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.1, a 5-year average ROIC of -81%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.

About Q/c Technologies

Q/c Technologies is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2014. Revenue went from $4M in 2014 to $2M in 2019, a decline of about 18.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 12863% over three years (dilution for shareholders).

Score: 1.2 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.1
Forward P/E—
P/FCF—
P/S—
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-425.9%
Shareholder yield0.0%
Intrinsic value vs. price−93%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-80.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————$2M$2M$3M$3M
Net income-$12M-$23M-$4M-$15M-$30M-$9M-$4M-$11M-$7M-$3M
Free cash flow-$11M——————-$9M-$5M-$4M
EPS (diluted)$-1.73$-216.17$-103.38$-227.71$-16.49$-12.08$-30.82$-108.12$-687.89$-540.61
Net margin——————-246.6%-651.4%-219.6%-111.6%
ROIC-35.8%-82.0%-108.9%-81.4%-95.6%——-116.0%-69.2%-77.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Q/c Technologies’s P/E ratio?

About 0.1, based on the last twelve months of diluted earnings per share.

Is Q/c Technologies stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Q/c Technologies pay a dividend?

Not currently.

Is Q/c Technologies a good stock to buy?

We do not give buy or sell advice. Q/c Technologies scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.